135 related articles for article (PubMed ID: 37389844)
1. Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-R.
Lakhotia R; Dunleavy K; Abramson JS; Link BK; Powell BL; Melani C; Lucas AN; Steinberg SM; Friedberg JW; Kahl BS; Little RF; Bartlett NL; Noy A; Wilson WH; Roschewski M
Blood Adv; 2023 Sep; 7(18):5320-5324. PubMed ID: 37389844
[TBL] [Abstract][Full Text] [Related]
2. Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma.
Roschewski M; Dunleavy K; Abramson JS; Powell BL; Link BK; Patel P; Bierman PJ; Jagadeesh D; Mitsuyasu RT; Peace D; Watson PR; Hanna WT; Melani C; Lucas AN; Steinberg SM; Pittaluga S; Jaffe ES; Friedberg JW; Kahl BS; Little RF; Bartlett NL; Fanale MA; Noy A; Wilson WH
J Clin Oncol; 2020 Aug; 38(22):2519-2529. PubMed ID: 32453640
[TBL] [Abstract][Full Text] [Related]
3. Low-intensity therapy in adults with Burkitt's lymphoma.
Dunleavy K; Pittaluga S; Shovlin M; Steinberg SM; Cole D; Grant C; Widemann B; Staudt LM; Jaffe ES; Little RF; Wilson WH
N Engl J Med; 2013 Nov; 369(20):1915-25. PubMed ID: 24224624
[TBL] [Abstract][Full Text] [Related]
4. Dose-adjusted EPOCH-R: a feasible alternative for Burkitt lymphoma in resource-constrained settings.
Jindal N; Jain A; Lad D; Prakash G; Khadwal A; Malhotra P
Br J Haematol; 2020 Sep; 190(6):e362-e363. PubMed ID: 32614462
[No Abstract] [Full Text] [Related]
5. Successful Use of EPOCH-R in 2 Young Adult Patients With Burkitt Lymphoma and Acute Kidney Injury: A Case Report.
Ross S; Eisenman K; Maloney KW
J Pediatr Hematol Oncol; 2019 Aug; 41(6):498-500. PubMed ID: 30095692
[TBL] [Abstract][Full Text] [Related]
6. [Clinical Efficacy and Prognostic Factors of Newly Diagnosed Children[JP] with Burkitt Lymphoma Treated by High-Dose and Short-Course Modified LMB Regimen ± Rituximab].
Wang BT; Dang HB; Wei YJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Apr; 28(2):529-534. PubMed ID: 32319391
[TBL] [Abstract][Full Text] [Related]
7. Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report.
Goldman S; Smith L; Galardy P; Perkins SL; Frazer JK; Sanger W; Anderson JR; Gross TG; Weinstein H; Harrison L; Shiramizu B; Barth M; Cairo MS
Br J Haematol; 2014 Nov; 167(3):394-401. PubMed ID: 25066629
[TBL] [Abstract][Full Text] [Related]
8. A rapidly growing lymphoma and tumor lysis syndrome in a toddler.
Green HL; Rytting ME; Cox CS
JAAPA; 2010 Aug; 23(8):30, 32-4. PubMed ID: 20821911
[No Abstract] [Full Text] [Related]
9. A case of primary gastric Burkitt-like lymphoma with chemotherapy-induced perforation.
Ergün M; Cindoruk M; Akyürek N; Akyol G; Ünal S
Turk J Gastroenterol; 2012 Jun; 23(3):299-300. PubMed ID: 22798124
[No Abstract] [Full Text] [Related]
10. Burkitt lymphomas failing dose-adjusted R-EPOCH (DA-R-EPOCH).
Aurer I; Bašić-Kinda S; Radman I; Ilić I; Grah JJ
Ann Hematol; 2014 Jan; 93(1):177-8. PubMed ID: 23636314
[No Abstract] [Full Text] [Related]
11. Dose-adjusted EPOCH-R for Burkitt lymphoma.
Hoelzer D
Clin Adv Hematol Oncol; 2014 Nov; 12(11):777-9. PubMed ID: 25674718
[No Abstract] [Full Text] [Related]
12. Case report and review of immunodeficiency-associated Burkitt lymphoma.
Johnson DH; Reske T; Ruiz M
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):e121-5. PubMed ID: 25701328
[No Abstract] [Full Text] [Related]
13. Dose-adjusted EPOCH and rituximab (DA-EPOCH-R) in older patients with high-risk aggressive diffuse large B-cell lymphoma: A real-life multicenter study by the Croatian Cooperative Group for Hematologic diseases (KroHem).
Mitrovic Z; Dujmovic D; Jaksic O; Kinda SB; Gacina P; Perisa V; Prka Z; Dreta B; Galusic D; Holik H; Pejsa V; Aurer I
Eur J Haematol; 2023 Jun; 110(6):725-731. PubMed ID: 36941738
[TBL] [Abstract][Full Text] [Related]
14. [Burkitt lymphoma, a diagnostic emergency].
Bredin S; Vergé V; Ribrag V
Rev Prat; 2016 Jan; 66(1):79-82. PubMed ID: 30512408
[TBL] [Abstract][Full Text] [Related]
15. Adding rituximab to CODOX-M/IVAC chemotherapy in the treatment of HIV-associated Burkitt lymphoma is safe when used with concurrent combination antiretroviral therapy.
Alwan F; He A; Montoto S; Kassam S; Mee M; Burns F; Edwards S; Wilson A; Tenant-Flowers M; Marcus R; Ardeshna KM; Bower M; Cwynarski K
AIDS; 2015 May; 29(8):903-10. PubMed ID: 25730506
[TBL] [Abstract][Full Text] [Related]
16. Validation of the Burkitt Lymphoma International Prognostic Index in patients treated with two prospective chemoimmunotherapy trials in Spain.
Ribera JM; García O; Buendía-Ureña B; Terol MJ; Vicent A; Vall-Llovera F; Bergua J; García-Cadenas I; Esteve J; Ribera J; Acuña-Cruz E; Herrera P; Hernández-Rivas JM; Abrisqueta P; González-Campos J; Rodríguez C; Bastos-Oreiro M; Genescà E; Caminos N; Queipo de Llano MP; Cladera A; Sancho JM;
Leuk Lymphoma; 2022 Aug; 63(8):1993-1996. PubMed ID: 35343365
[No Abstract] [Full Text] [Related]
17. A 5-drug regimen maximizing the dose of cyclophosphamide is effective therapy for adult Burkitt or Burkitt-like lymphomas.
Kujawski LA; Longo WL; Williams EC; Turman NJ; Brandt N; Mosher DF; Eickhoff JC; Kahl BS
Cancer Invest; 2007 Mar; 25(2):87-93. PubMed ID: 17453819
[TBL] [Abstract][Full Text] [Related]
18. DA-EPOCH-R in Burkitt Lymphoma: Is It Enough for High-Risk Disease?
Hertzberg M; Joske DJL; Gandhi MK
J Clin Oncol; 2020 Nov; 38(31):3722-3723. PubMed ID: 32931401
[No Abstract] [Full Text] [Related]
19. Burkitt lymphoma - no impact of HIV status on outcomes with rituximab-based chemoimmunotherapy.
Tan JY; Qiu TY; Chiang J; Tan YH; Yang VS; Chang EWY; Poon E; Somasundaram N; Farid M; Tao M; Lim ST; Chan JY
Leuk Lymphoma; 2023 Mar; 64(3):586-596. PubMed ID: 35188049
[TBL] [Abstract][Full Text] [Related]
20. Adult Burkitt lymphoma: advances in diagnosis and treatment.
Aldoss IT; Weisenburger DD; Fu K; Chan WC; Vose JM; Bierman PJ; Bociek RG; Armitage JO
Oncology (Williston Park); 2008 Nov; 22(13):1508-17. PubMed ID: 19133605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
